Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler bought 100,000 shares of Biodesix stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average cost of $10.02 per share, for a total transaction of $1,002,000.00. Following the acquisition, the director owned 655,810 shares of the company's stock, valued at $6,571,216.20. This represents a 17.99% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Biodesix Stock Down 3.3%
Shares of Biodesix stock opened at $9.79 on Friday. Biodesix, Inc. has a 52-week low of $5.26 and a 52-week high of $31.97. The company has a 50 day moving average of $24.23 and a 200 day moving average of $18.88. The company has a quick ratio of 2.85, a current ratio of 2.96 and a debt-to-equity ratio of 5.43. The company has a market capitalization of $108.57 million, a P/E ratio of -3.55 and a beta of 0.65.
Biodesix (NASDAQ:BDSX - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.75) EPS for the quarter, hitting the consensus estimate of ($0.75). Biodesix had a negative net margin of 25.74% and a negative return on equity of 442.34%. The company had revenue of $24.04 million during the quarter, compared to analysts' expectations of $27.48 million. As a group, research analysts forecast that Biodesix, Inc. will post -2.95 EPS for the current fiscal year.
Institutional Trading of Biodesix
Several institutional investors have recently modified their holdings of BDSX. Cetera Investment Advisers boosted its holdings in shares of Biodesix by 20.0% in the 1st quarter. Cetera Investment Advisers now owns 12,000 shares of the company's stock valued at $174,000 after buying an additional 2,000 shares in the last quarter. Allworth Financial LP acquired a new stake in Biodesix during the 2nd quarter worth $112,000. HighTower Advisors LLC acquired a new stake in Biodesix during the 3rd quarter worth $228,000. AIGH Capital Management LLC lifted its position in Biodesix by 1.1% in the third quarter. AIGH Capital Management LLC now owns 686,021 shares of the company's stock valued at $20,464,000 after acquiring an additional 7,693 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in Biodesix in the first quarter valued at $157,000. Hedge funds and other institutional investors own 20.96% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on BDSX. Canaccord Genuity Group increased their target price on Biodesix from $27.00 to $35.00 and gave the company a "buy" rating in a report on Monday, August 10th. HC Wainwright decreased their price target on Biodesix from $38.00 to $34.00 and set a "buy" rating for the company in a report on Monday. TD Cowen reaffirmed a "buy" rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. Weiss Ratings raised Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 8th. Finally, Lake Street Capital dropped their price objective on Biodesix from $40.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $34.20.
Read Our Latest Stock Report on BDSX
Biodesix News Summary
These are some of the BDSX news items that stood out recently:
- Positive Sentiment: Director Jack Schuler bought 100,000 shares for about $1.0 million, increasing his direct stake by roughly 18% to 655,810 shares. The purchase may signal confidence in the company. SEC filing
- Positive Sentiment: HC Wainwright maintained its Buy rating and $34 price target, despite lowering its earnings forecasts. HC Wainwright estimates article
- Negative Sentiment: Johnson Fistel said it is investigating potential securities claims related to Biodesix’s statements and disclosures after the sharp November 6 stock decline. This is an investigation, not a finding of wrongdoing, but it may add legal and reputational uncertainty. Investigation announcement
Biodesix Company Profile
(
Get Free Report)
Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions. Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
